Silo Pharma announces its initial Bitcoin purchase, expanding its cryptocurrency treasury strategy amid growing digital asset confidence.
Quiver AI Summary
Silo Pharma, Inc. has announced its initial purchase of Bitcoin as part of its strategy to grow its cryptocurrency reserve, signaling confidence in Bitcoin's role as a store of value and a hedge against market volatility. CEO Eric Weisblum emphasized the company's commitment to investing in digital assets, following previous purchases of Ethereum, RSC, and Solano tokens. Silo Pharma, which focuses on developing treatments for underserved conditions like psychiatric disorders and chronic pain, plans to expand its cryptocurrency holdings further as part of its diversified treasury strategy. The company emphasizes its innovative therapeutic programs and research collaborations while also noting the uncertainties inherent in its forward-looking statements.
Potential Positives
- Silo Pharma's initial purchase of Bitcoin enhances its crypto reserve strategy, showcasing a commitment to diversifying its asset portfolio.
- The company expresses confidence in Bitcoin as a store of value and a hedge against market volatility, indicating a proactive financial strategy.
- Silo's investment in multiple cryptocurrencies, including Ethereum, RSC, and Solano tokens, reflects a broad approach to digital asset growth and potential value creation.
- The collaboration with leading universities and laboratories for therapeutic research positions Silo Pharma as a forward-thinking company in the biopharmaceutical space.
Potential Negatives
- Investing in cryptocurrencies such as Bitcoin and Ethereum may be viewed as a diversion from Silo's primary focus on developing biopharmaceuticals, potentially raising concerns among investors about the company’s strategic direction.
- The use of speculative digital assets could increase financial volatility and uncertainty for the company, which may impact investor confidence and lead to scrutiny from stakeholders.
- The forward-looking statements disclaimer indicates significant risks and uncertainties that could impede the company’s ability to achieve its goals, which may concern investors about the reliability of management's forecasts.
FAQ
What is Silo Pharma's recent purchase in cryptocurrency?
Silo Pharma recently announced its initial purchase of Bitcoin as part of its crypto reserve strategy.
Why did Silo invest in Bitcoin?
The CEO, Eric Weisblum, stated that the investment reflects the company's belief in Bitcoin as a store of value and a hedge against market volatility.
What other cryptocurrencies has Silo Pharma purchased?
In addition to Bitcoin, Silo has purchased Ethereum, RSC, and Solano tokens to diversify its treasury reserve strategy.
What is Silo Pharma's primary business focus?
Silo Pharma focuses on developing biopharmaceuticals that address underserved conditions like psychiatric disorders and chronic pain.
How does Silo Pharma conduct its research?
The company conducts its research in collaboration with leading universities and laboratories to advance its therapeutic programs.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$SILO Insider Trading Activity
$SILO insiders have traded $SILO stock on the open market 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $SILO stock by insiders over the last 6 months:
- ERIC WEISBLUM (Chief Executive Officer) purchased 10,000 shares for an estimated $4,329
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$SILO Hedge Fund Activity
We have seen 8 institutional investors add shares of $SILO stock to their portfolio, and 4 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ADVISORSHARES INVESTMENTS LLC added 60,000 shares (+48.3%) to their portfolio in Q2 2025, for an estimated $37,800
- TWO SIGMA SECURITIES, LLC added 43,219 shares (+inf%) to their portfolio in Q2 2025, for an estimated $27,227
- URSA FUND MANAGEMENT, LLC added 37,500 shares (+inf%) to their portfolio in Q2 2025, for an estimated $23,625
- XTX TOPCO LTD added 26,823 shares (+inf%) to their portfolio in Q2 2025, for an estimated $16,898
- CONNING INC. removed 20,000 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $12,600
- CITIGROUP INC added 9,334 shares (+609.3%) to their portfolio in Q2 2025, for an estimated $5,880
- CITADEL ADVISORS LLC added 7,471 shares (+36.1%) to their portfolio in Q2 2025, for an estimated $4,706
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
SARASOTA, FL, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or “the Company), a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company, today announced its initial purchase of Bitcoin under its crypto reserve strategy targeting multi-chain asset growth.
“Silo’s latest strategic crypto purchase signals our conviction in Bitcoin as both store of value and a hedge against general financial market volatility,” said Eric Weisblum, CEO of Silo. “Overall, the four crypto investments we have made so far underscore our Company’s confidence in the growing adoption and value creation opportunities available through a digital asset treasury portfolio.”
Silo’s initial purchase of Bitcoin follows recently announced crypto purchases of Ethereum, RSC, and Solano tokens. The Company plans to continue purchasing various crypto tokens as part of its diversified treasury reserve strategy.
About Silo Pharma
Silo Pharma is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company. Its therapeutic focus is on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The Company’s portfolio includes innovative programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer’s disease and multiple sclerosis. Silo’s research is conducted in collaboration with leading universities and laboratories.
silopharma.com
Forward-Looking Statements
This news release contains "forward-looking statements" within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified using words “could”, “believe”, “anticipate”, “intend”, “estimate”, “expect”, “may”, “continue”, “predict”, “potential”, and similar expressions that are intended to identify forward-looking statements. Such statements involve known and unknown risks, uncertainties, and other factors that could cause the actual results of Silo Pharma, Inc. (“Silo” or “the Company”) to differ materially from the results expressed or implied by such statements, including changes to anticipated sources of revenues, future economic and competitive conditions, difficulties in developing the Company’s technology platforms, retaining and expanding the Company’s customer base, fluctuations in consumer spending on the Company’s products and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company disclaims any obligations to publicly update or release any revisions to the forward-looking information contained in this press release, whether as a result of new information, future events, or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events except as required by law.
Contact
800-705-0120
[email protected]
